Compare RENT & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RENT | NVCT |
|---|---|---|
| Founded | 2009 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.3M | 220.0M |
| IPO Year | 2021 | 2021 |
| Metric | RENT | NVCT |
|---|---|---|
| Price | $4.89 | $7.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | ★ 52.1K | 49.8K |
| Earning Date | 04-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.11 | N/A |
| EPS | ★ 5.10 | N/A |
| Revenue | ★ $306,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.72 | N/A |
| P/E Ratio | $0.95 | ★ N/A |
| Revenue Growth | ★ 2.68 | N/A |
| 52 Week Low | $3.69 | $5.55 |
| 52 Week High | $10.13 | $11.52 |
| Indicator | RENT | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 34.64 |
| Support Level | $4.36 | $5.77 |
| Resistance Level | $4.92 | $8.46 |
| Average True Range (ATR) | 0.28 | 0.43 |
| MACD | 0.10 | -0.14 |
| Stochastic Oscillator | 81.88 | 5.48 |
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe to, or buy designer apparel and accessories. The company gives customers access to its unlimited closet through its subscription offering (Subscription) or the ability to rent a-la-carte through its reserve offering (Reserve). The company also gives its subscribers and customers the ability to buy its products through its Resale offering. The Closet in the Cloud offers a wide assortment of items for every occasion, from evening wear and accessories to ready-to-wear, workwear, denim, casual, maternity, outerwear, blouses, knitwear, loungewear, jewelry, handbags, activewear, and ski wear.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.